Noninfectious and Nonmalignant Complications of Anti-TNF Therapy

作者: Uni Wong , Raymond K. Cross

DOI: 10.1007/978-3-319-60276-9_14

关键词: Anti-TNF therapyInjection site reactionGastroenterologyInjection siteMedicineHeart failureInflammatory bowel diseaseModerate to severePathophysiologyDiscontinuationInternal medicine

摘要: Anti-TNF therapies are commonly used in the treatment of moderate to severe inflammatory bowel disease. The noninfectious and nonmalignant complications anti-TNF therapy include infusion or injection site reactions, psoriasiform eczematous eruptions, lupus-like reaction, hepatotoxicity, demyelination, heart failure. Infusion/injection dermatologic reactions often can be managed with supportive care without discontinuation anti-TNF. Early recognition management these is important initiate if indicated, minimize symptoms, transition other necessary. This chapter focuses on clinical presentation, pathophysiology, diagnostic evaluation, therapy.

参考文章(108)
Lauren A. George, Akash Gadani, Raymond K. Cross, Guruprasad Jambaulikar, Leyla J. Ghazi, Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease Digestive Diseases and Sciences. ,vol. 60, pp. 3424- 3430 ,(2015) , 10.1007/S10620-015-3763-0
G. Cullen, D. Kroshinsky, A. S. Cheifetz, J. R. Korzenik, Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature Alimentary Pharmacology & Therapeutics. ,vol. 34, pp. 1318- 1327 ,(2011) , 10.1111/J.1365-2036.2011.04866.X
D. Pugliese, L. Guidi, P. M. Ferraro, M. Marzo, C. Felice, L. Celleno, R. Landi, G. Andrisani, F. Pizzolante, I. De Vitis, A. Papa, G. L. Rapaccini, A. Armuzzi, Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti‐TNF alpha: 5‐year follow‐up study Alimentary Pharmacology & Therapeutics. ,vol. 42, pp. 880- 888 ,(2015) , 10.1111/APT.13352
M. Massarotti, B. Marasini, Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. International Journal of Immunopathology and Pharmacology. ,vol. 22, pp. 547- 549 ,(2009) , 10.1177/039463200902200234
Fong-Kuei F. Cheng, Edward E. Bridges, John D. Betteridge, Drug-Induced Liver Injury From Initial Dose of Infliximab Military Medicine. ,vol. 180, pp. e723- e724 ,(2015) , 10.7205/MILMED-D-14-00485
E. Andreadou, E. Kemanetzoglou, Ch. Brokalaki, M. E. Evangelopoulos, C. Kilidireas, A. Rombos, E. Stamboulis, Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature Case reports in neurological medicine. ,vol. 2013, pp. 671935- 671935 ,(2013) , 10.1155/2013/671935
Angelique N. Collamer, Daniel F. Battafarano, Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis Seminars in Arthritis and Rheumatism. ,vol. 40, pp. 233- 240 ,(2010) , 10.1016/J.SEMARTHRIT.2010.04.003
Maria-Eugenia Ariza, Marshall V. Williams, A human endogenous retrovirus K dUTPase triggers a TH1, TH17 cytokine response: does it have a role in psoriasis? Journal of Investigative Dermatology. ,vol. 131, pp. 2419- 2427 ,(2011) , 10.1038/JID.2011.217
Rafael Denadai, Fábio Vieira Teixeira, Flavio Steinwurz, Ricardo Romiti, Rogério Saad-Hossne, Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases☆ Journal of Crohn's and Colitis. ,vol. 7, pp. 517- 524 ,(2013) , 10.1016/J.CROHNS.2012.08.007
Gabriel J. Tobon, Carlos Cañas, Juan-Jose Jaller, Juan-Carlos Restrepo, Juan-Manuel Anaya, Serious liver disease induced by infliximab Clinical Rheumatology. ,vol. 26, pp. 578- 581 ,(2007) , 10.1007/S10067-005-0169-Y